Search Results
Search for other papers by Daniel Bell in
Google Scholar
PubMed
Search for other papers by Julia Hale in
Google Scholar
PubMed
Search for other papers by Cara Go in
Google Scholar
PubMed
Search for other papers by Ben G Challis in
Google Scholar
PubMed
Search for other papers by Tilak Das in
Google Scholar
PubMed
Search for other papers by Brian Fish in
Google Scholar
PubMed
Department of Medical Genetics, Cambridge University, Cambridge, UK
Search for other papers by Ruth T Casey in
Google Scholar
PubMed
Primary hyperparathyroidism (pHPT) is a common endocrine disorder that can be cured by parathyroidectomy; patients unsuitable for surgery can be treated with cinacalcet. Availability of surgery may be reduced during COVID-19, and cinacalcet can be used as bridging therapy. In this single-centre retrospective analysis, we investigated the utility and safety of cinacalcet in patients with pHPT receiving cinacalcet between March 2019 and July 2020, including pre-parathyroidectomy bridging. We reviewed and summarised the published literature. Cinacalcet dosages were adjusted by endocrinologists to achieve target calcium < 2.70 mmol/L. Eighty-six patients were identified, with the most achieving target calcium (79.1%) with a mean dose of 39.4 mg/day (±17.1 mg/day) for a median duration of 35 weeks (1–178 weeks). Calcium was normalised in a median time of 5 weeks. The majority of patients commenced cinacalcet of 30 mg/day (78 patients) with the remainder at 60 mg/day (8 patients). Forty-seven patients commencing lower dose cinacalcet (30 mg/day) achieved target calcium without requiring 60 mg/day. Baseline PTH was significantly higher in patients requiring higher doses of cinacalcet. 18.6% of patients reported adverse reactions and 4.7% discontinued cinacalcet. Patients treated with cinacalcet pre-parathyroidectomy required a higher dose and fewer achieved target calcium compared to medical treatment with cinacalcet alone. Post-operative calcium was similar to patients who were not given pre-parathyroidectomy cinacalcet. In summary, cinacalcet at an initial dose of 30 mg/day is safe and useful for achieving target calcium in patients with symptomatic or severe hypercalcaemia in pHPT, including those treated for pre-parathyroidectomy. We propose a PTH threshold of >30 pmol/L to initiate at a higher dose of 60 mg/day.
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
IMED Biotech Unit, Clinical Discovery Unit, AstraZeneca, UK
Search for other papers by Benjamin G Challis in
Google Scholar
PubMed
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by Andrew S Powlson in
Google Scholar
PubMed
Search for other papers by Ruth T Casey in
Google Scholar
PubMed
Search for other papers by Carla Pearson in
Google Scholar
PubMed
Search for other papers by Brian Y Lam in
Google Scholar
PubMed
Search for other papers by Marcella Ma in
Google Scholar
PubMed
Search for other papers by Deborah Pitfield in
Google Scholar
PubMed
Search for other papers by Giles S H Yeo in
Google Scholar
PubMed
Search for other papers by Edmund Godfrey in
Google Scholar
PubMed
Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by Heok K Cheow in
Google Scholar
PubMed
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by V Krishna Chatterjee in
Google Scholar
PubMed
Search for other papers by Nicholas R Carroll in
Google Scholar
PubMed
Search for other papers by Ashley Shaw in
Google Scholar
PubMed
Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by John R Buscombe in
Google Scholar
PubMed
Search for other papers by Helen L Simpson in
Google Scholar
PubMed
Objective
In adults with hyperinsulinaemic hypoglycaemia (HH), in particular those with insulinoma, the optimal diagnostic and management strategies remain uncertain. Here, we sought to characterise the biochemical and radiological assessment, and clinical management of adults with HH at a tertiary centre over a thirteen-year period.
Design
Clinical, biochemical, radiological and histological data were reviewed from all confirmed cases of adult-onset hyperinsulinaemic hypoglycaemia at our centre between 2003 and 2016. In a subset of patients with stage I insulinoma, whole-exome sequencing of tumour DNA was performed.
Results
Twenty-nine patients were identified (27 insulinoma, including 6 subjects with metastatic disease; 1 pro-insulin/GLP-1 co-secreting tumour; 1 activating glucokinase mutation). In all cases, hypoglycaemia (glucose ≤2.2 mmol/L) was achieved within 48 h of a supervised fast. At fast termination, subjects with stage IV insulinoma had significantly higher insulin, C-peptide and pro-insulin compared to those with insulinoma staged I–IIIB. Preoperative localisation of insulinoma was most successfully achieved with EUS. In two patients with inoperable, metastatic insulinoma, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE rapidly restored euglycaemia and lowered fasting insulin. Finally, in a subset of stage I insulinoma, whole-exome sequencing of tumour DNA identified the pathogenic Ying Yang-1 (YY1) somatic mutation (c.C1115G/p.T372R) in one tumour, with all tumours exhibiting a low somatic mutation burden.
Conclusion
Our study highlights, in particular, the utility of the 48-h fast in the diagnosis of insulinoma, EUS for tumour localisation and the value of PRRT therapy in the treatment of metastatic disease.
